文献速递妇科

MCC950阻断NLRP3炎症小体抑制子宫腺肌病中的迁移和侵袭

Blockage of the NLRP3 inflammasome by MCC950 inhibits migration and invasion in adenomyosis.
PubMed 文献 · Reprod Biomed Online · 2024-06-11

本研究检测子宫腺肌病患者子宫内膜中NLRP3炎症小体成分表达升高,敲低NLRP3或使用抑制剂MCC950可抑制子宫内膜细胞迁移、侵袭和上皮-间质转化,并在小鼠模型中减轻子宫腺肌病严重程度。

要点

  • 子宫腺肌病患者异位和在位子宫内膜中NLRP3炎症小体成分表达升高。
  • 敲低NLRP3抑制子宫内膜细胞和原代子宫内膜细胞的迁移、侵袭及上皮-间质转化(P<0.0001)。
  • MCC950减轻小鼠子宫腺肌病模型的严重程度(P<0.01),显示治疗作用。

核心结论

  • NLRP3可增强子宫腺肌病中人子宫内膜细胞的迁移、侵袭和上皮-间质转化。
  • NLRP3抑制剂MCC950有效减少子宫内膜细胞的迁移和侵袭。
  • 在小鼠子宫腺肌病模型中,MCC950通过减轻子宫腺肌病严重程度表现出治疗作用。

研究设计与样本

  • 获取子宫腺肌病患者和对照的子宫内膜新鲜冷冻组织和石蜡标本。
  • 采用蛋白质印迹、实时定量聚合酶链反应和免疫组织化学评估NLRP3炎症小体成分表达。
  • 从子宫腺肌病患者子宫分离原代在位子宫内膜基质细胞。
  • 使用小干扰RNA敲低NLRP3后,通过EdU、CCK8、Transwell实验和蛋白质印迹评估增殖、侵袭和上皮-间质转化。
  • 建立小鼠子宫腺肌病模型以评估NLRP3抑制剂MCC950对子宫腺肌病形成的影响。

主要发现

  • NLRP3炎症小体成分在子宫腺肌病患者异位或在位子宫内膜中表达升高。
  • 敲低NLRP3抑制子宫内膜细胞和原代子宫内膜细胞的迁移、侵袭和上皮-间质转化(P<0.0001)。
  • MCC950显著减少子宫内膜细胞的迁移和侵袭(P<0.01),并显著减少原代子宫内膜细胞的迁移和侵袭(P<0.0001)。
  • 在小鼠子宫腺肌病模型中,MCC950对子宫腺肌病严重程度有减轻作用(P<0.01)。

关键数值与推荐

  • NLRP3敲低抑制迁移、侵袭和上皮-间质转化:P<0.0001。
  • MCC950减少子宫内膜细胞迁移和侵袭:P<0.01;减少原代子宫内膜细胞迁移和侵袭:P<0.0001。
  • MCC950减轻小鼠子宫腺肌病严重程度:P<0.01。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Does the NOD-like receptor protein 3 (NLRP3) inflammasome have an effect in adenomyosis? DESIGN: Fresh-frozen endometrial tissues and paraffin specimens were obtained from endometrial tissues from patients with adenomyosis and controls. Western blot, quantitative real-time polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC) were applied to assess expression of the NLRP3 inflammasome components. Primary eutopic endometrial stromal cells were isolated from the uteri of patients with adenomyosis. After NLRP3 was knocked down using small interfering RNA, proliferation, invasion and epithelial-mesenchymal transition (EMT) were evaluated using EdU, CCK8, transwell assays and western blot. Importantly, a mouse model of adenomyosis was established to evaluate the effects of the NLRP3 inhibitor MCC950 on the formation of adenomyosis. RESULTS: Expression of the NLRP3 inflammasome components was elevated in the ectopic or eutopic endometrium of patients with adenomyosis. NLRP3 knockdown inhibited migration, invasion and EMT in endometrial cells and primary endometrial cells (P < 0.0001). MCC950, which blocks the NLRP3 inflammasome, reduced migration and invasion of endometrial cells (P < 0.01) and primary endometrial cells (P < 0.0001) considerably. Importantly, in the mouse model of adenomyosis, MCC950 had a mitigating effect on the severity of adenomyosis (P < 0.01). CONCLUSIONS: NLRP3 was found to enhance migration, invasion and EMT of human endometrial cells in adenomyosis. Notably, the NLRP3 inhibitor MCC950 reduced migration and invasion of endometrial cells effectively. Furthermore, in the mouse model of adenomyosis, MCC950 exhibited a therapeutic effect by alleviating the severity of adenomyosis.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Liu Y, Jiang Z, Zhang L, et al. Blockage of the NLRP3 inflammasome by MCC950 inhibits migration and invasion in adenomyosis. Reprod Biomed Online. 2024. PMID: 39121559. doi:10.1016/j.rbmo.2024.104319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。